May 17, 2019 06:39 AM EDTUpdated May 21, 12:02 PM

Four years after EU approval, NICE finally backs Revlimid use in certain first-line multiple myeloma patients

Natalie Grover

Reporter

Four years after the European Commission sanctioned the use of Celgene’s flagship Revlimid to treat adults with previously-untreated multiple myeloma who are not eligible …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Four years after EU approval, NICE finally backs Revlimid use in certain first-line multiple myeloma patients

Natalie Grover

Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Four years af­ter EU ap­proval, NICE fi­nal­ly backs Revlim­id use in cer­tain first-line mul­ti­ple myelo­ma pa­tients

Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Four years after EU approval, NICE finally backs Revlimid use in certain first-line multiple myeloma patients